RT Journal Article
SR Electronic
T1 Real-time IP-10 measurements as a new tool for inflammation regulation within a clinical decision support protocol for managing severe COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.21.20158782
DO 10.1101/2020.07.21.20158782
A1 Lev, Shaul
A1 Gottesman, Tamar
A1 Levin, Gal Sahaf
A1 Lederfein, Doron
A1 Berkov, Evgeny
A1 Diker, Dror
A1 Zaidman, Aliza
A1 Nutman, Amir
A1 Ber, Tahel Ilan
A1 Angel, Alon
A1 Kellerman, Lior
A1 Barash, Eran
A1 Navon, Roy
A1 Boico, Olga
A1 Israeli, Yael
A1 Rosenberg, Michal
A1 Gelman, Amir
A1 Kalfon, Roy
A1 Simon, Einav
A1 Avni, Noa
A1 Hainrichson, Mary
A1 Zarchin, Oren
A1 Gottlieb, Tanya M.
A1 Oved, Kfir
A1 Eden, Eran
A1 Tadmor, Boaz
YR 2020
UL http://medrxiv.org/content/early/2020/07/22/2020.07.21.20158782.abstract
AB The challenge of treating severely ill COVID-19 patients is particularly great due to the need to simultaneously manage oxygenation and the inflammatory state without compromising viral clearance. Currently, there are many tools to aid in oxygen management and in monitoring viral replication. However, predictive biomarkers for monitoring the host immune response across COVID-19 disease stages and specifically, for titrating immunomodulatory therapy are lacking. We utilized a recently cleared platform (MeMed Key™) that enables rapid and easy serial measurement of IP-10, a host protein implicated in lung injury due to viral-induced hyperinflammation. A dynamic clinical decision support protocol was employed for managing SARS-CoV-2 positive patients admitted to a COVID-19 dedicated medical center run by Clalit Health Services. This is the first protocol to include real-time measurements of IP-10 as a potential aid for regulating inflammation. Overall, 502 serial real-time IP-10 measurements were performed on 52 patients recruited between 7th April 2020 to 10th May 2020, with 12 patients admitted to the intensive care unit (ICU). IP-10 levels correlated with increased COVID-19 severity score and ICU admission. Within the ICU admitted patients, the number of days with IP-10 measurements >1,000 pg/ml was associated with mortality. Upon administration of corticosteroid immunomodulatory therapy, a significant decrease in IP-10 levels was observed. Real-time IP-10 monitoring represents a new tool to aid in management and therapeutic decisions relating to the inflammatory status of COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04389645Funding StatementCartridges and devices were supplied by MeMed, Israel.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Helsinki Committee, Hasharon, Rabin Medical Center, Petah Tikva, IsraelAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will not be publicly available.